# Madrigal (MDGL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/MDGL
## Company Profile
- Ticker: MDGL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 535.27 USD
- Market cap: 10440985734.74 USD
- Last updated: 2026-08-11
## Business Overview
### Commercial MASH Leader
Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Its lead product, Rezdiffra, is a once-daily oral liver-directed THR-beta agonist and the first medicine approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis.
### Rezdiffra Growth Platform
Rezdiffra is the company's commercial foundation. Second-quarter 2026 net sales reached $364.3 million, up 71% year over year, and more than 49,000 patients were on therapy as of June 30, 2026. Madrigal is investing in field-force expansion, disease education, real-world evidence, and physician adoption to maximize the long-term value of the launch.
### Pipeline Anchored by Combination Therapy
Madrigal is building beyond Rezdiffra through MGL-2086, an oral small-molecule GLP-1 receptor agonist and orforglipron derivative. The company initiated Phase 1 dosing in June 2026 as part of a strategy to develop once-daily oral combination treatments for MASH anchored by Rezdiffra.
### Strategic Position
Madrigal is best understood as a commercial-stage MASH company with a foundational therapy and a strategy to defend leadership through IP, evidence generation, and combination development. Its differentiation rests on Rezdiffra's first-mover position, expanding patient base, and potential to address both liver and cardiometabolic risk.
## Why The Stock Is Moving

As of Aug 11, 2026, MDGL closed up 3.87% at $535.27. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
- Future data from the Phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis.

## Recent News
- 2026-08-06 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-52cfb9fa) — Source: Madrigal
- 2026-08-06 12:00 EST — [Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-gro-04739d27) — Source: Madrigal
- 2026-07-30 11:00 EST — [Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provi-4eca043e) — Source: Madrigal
- 2026-07-16 12:00 EST — [Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-ho-8492a4a5) — Source: Madrigal
- 2026-07-13 12:00 EST — [Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-f27ea704) — Source: Madrigal